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scientiﬁc articles presented during 2016 at the First International
Conference on Health Research held at the Hochschule Hannover,
University of Applied Sciences and Arts, in Hannover, Germany.
This special edition contains selected peer-reviewed articles
covering topics presented at the conference. From Germany, there
is a scholarly discourse that interrogates the view that clinical
research involving humans is only acceptable if it involves the
potential for beneﬁt. This was done while considering the ongoing
conversation on whether the overriding ethical considerations
should weigh more in favor of indirect beneﬁts (ie, collective or
beneﬁt for society, excluding or including the trial patient in the
long-term) than direct beneﬁts. This was made more relevant by
the fact that ethical guidelines, such as the Declaration of Helsinki, in
its latest version, do not precisely favor a particular type of beneﬁt.
However, it was rationalized from an ethical view point that each
beneﬁt achieved for individual patients as part of a clinical trial
testing new treatments, drugs, or medicinal products might be seen
as social beneﬁt as well, and even more when the tested drug or
device will be made available for all patients of the country where
the clinical trial was conducted after its market approval.
A Greek bioethicist argues in defense of medically enhancing
humanmorality. The author expresses the view that moral enhance-
ment by means of pharmaceutical interventions might be a moral
duty based on Kantian ethics, and thus deﬂects arguments that focus
on an individual’s autonomy and free will. It was expressed that
medically intervening with humans in such a way as to even
eliminate morally unjustiﬁable choices does not necessarily com-
promise either free will or the autonomy of moral agents.
The argument above resonates with the choices that should be
made when considering the roads to health in developing countries.
Thus, researchers from Africa and Europe who have an interest in
developing countries challenge the World Health Organization
deﬁnition of health (as “not merely the absence of sickness,”) in
the light of ethnomedical beliefs about the cause(s) of illness. The
World Health Organization deﬁnition has guided scientists and
health care providers in the Western world in the development of
health care programs in non-Western societies that are based on
biomedical concepts. However, ethnomedical beliefs about the
cause(s) of illness have given rise to alternative theories of health,
sickness, and treatment approaches in the developing world. The
deﬁnition of health in these settings tends to orient toward cultural
beliefs, traditional practices, and social relationships. It is argued
that human beings are guided in health care decisions by past
experiences, family and friends, social networks, cultural beliefs,
customs, tradition, professional knowledge, and intuition. No med-
ical system has been shown to address all of these elements, hence
the need for collaboration, acceptance, and partnership between allx.doi.org/10.1016/j.curtheres.2017.10.001
3X/& 2017 The Authors. Published by Elsevier Inc. This is an open access article usystems of care in cultural communities. They posit that perhaps
mutual exclusiveness, rather than inclusiveness, of the 2 dominant
health systems is the greatest obstacle to health in Nigeria.
Researchers from the Middle East argue that providing for the
health needs of developing countries through clinical trials of drugs or
devices in development could be ﬁnancially rewarding considering the
economics of most developing countries. It is highlighted that these
communities are most in need of drugs for infectious and communic-
able diseases such as sexually transmitted diseases. These countries
are ready-to-exploit territories for the development of innovative
pharmaceutical products. This opportunity has been made more
appealing by an increase in wealth and longevity. A change of lifestyle
is slowly taking place in most developing countries, accompanied by a
shift in disease trends. A disproportionately faster rise in the incidence
of noncommunicable diseases such as cardiovascular illnesses, dia-
betes, and cancers has been noted in emerging markets, mimicking
the patterns seen in their Western counterparts. The challenges faced
by the pharma industries in their attempts to conquer the
emerging markets were identiﬁed as infrastructure development,
cost-containment policies, and value-driven drug evaluation. To over-
come these hurdles, new strategies need to be adopted by pharma-
ceutical companies. Adequate tailoring and gains in the market are
among the top strategies to be considered.
Overall, this special edition contains a mix of intellectual discus-
sions on the philosophical dimensions of morality that should under-
pin clinical interventions while addressing the knotty issues of
individual autonomy and choice. The meeting from which these came
dealt with ethical issues that guide the conduct of clinical trials while
highlighting the sociocultural considerations that may limit the provi-
sion of health services in communities if they are based solely on
biomedical concepts. It further highlights the gains possible from
investing in the clinical trial arena within developing countries.
As a conference organizer, I hope that you enjoy reading these articles
and the accompanying abstracts and I look forward to your feedback.Gerhard Fortwengel, PhD, MPH*
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